These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35598411)

  • 1. New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models.
    Di Sarno V; Giovannelli P; Medina-Peris A; Ciaglia T; Di Donato M; Musella S; Lauro G; Vestuto V; Smaldone G; Di Matteo F; Bifulco G; Castoria G; Migliaccio A; Fernandez-Carvajal A; Campiglia P; Gomez-Monterrey I; Ostacolo C; Bertamino A
    Eur J Med Chem; 2022 Aug; 238():114435. PubMed ID: 35598411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of TRPM8 antagonists in prostate cancer.
    Di Donato M; Ostacolo C; Giovannelli P; Di Sarno V; Monterrey IMG; Campiglia P; Migliaccio A; Bertamino A; Castoria G
    Sci Rep; 2021 Dec; 11(1):23232. PubMed ID: 34853378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies.
    Genovesi S; Moro R; Vignoli B; De Felice D; Canossa M; Montironi R; Carbone FG; Barbareschi M; Lunardi A; Alaimo A
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of adrenal derived androgens in castration resistant prostate cancer.
    Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
    J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRPM8 channel as a novel molecular target in androgen-regulated prostate cancer cells.
    Asuthkar S; Velpula KK; Elustondo PA; Demirkhanyan L; Zakharian E
    Oncotarget; 2015 Jul; 6(19):17221-36. PubMed ID: 25980497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and functional properties of TRPM8 channels in prostate tumor cells.
    Valero M; Morenilla-Palao C; Belmonte C; Viana F
    Pflugers Arch; 2011 Jan; 461(1):99-114. PubMed ID: 21052713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
    Nishizawa K; Hattahara K; Onishi H; Yoshida T
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro and In Vivo Pharmacological Characterization of a Novel TRPM8 Inhibitor Chemotype Identified by Small-Scale Preclinical Screening.
    Iraci N; Ostacolo C; Medina-Peris A; Ciaglia T; Novoselov AM; Altieri A; Cabañero D; Fernandez-Carvajal A; Campiglia P; Gomez-Monterrey I; Bertamino A; Kurkin AV
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
    Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
    Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 18. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.
    Terrisse S; Goubet AG; Ueda K; Thomas AM; Quiniou V; Thelemaque C; Dunsmore G; Clave E; Gamat-Huber M; Yonekura S; Ferrere G; Rauber C; Pham HP; Fahrner JE; Pizzato E; Ly P; Fidelle M; Mazzenga M; Costa Silva CA; Armanini F; Pinto F; Asnicar F; Daillère R; Derosa L; Richard C; Blanchard P; Routy B; Culine S; Opolon P; Silvin A; Ginhoux F; Toubert A; Segata N; McNeel DG; Fizazi K; Kroemer G; Zitvogel L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.